New combo therapy aims to turn inoperable liver cancer into operable

NCT ID NCT07480382

Not yet recruiting Disease control Sponsor: Hong Wu Source: ClinicalTrials.gov ↗

First seen Mar 27, 2026 · Last updated May 15, 2026 · Updated 9 times

Summary

This study tests a new approach for people with liver cancer that cannot be removed by surgery. The treatment combines a procedure to grow the healthy part of the liver, a type of chemoembolization, and two drugs (tislelizumab and lenvatinib) to shrink the tumor enough for surgery. The goal is to see how many patients can then have their cancer completely removed, and to check the safety of this combined treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INITIALLY UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 614000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.